Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is attractive on a risk-adjusted basis because its valuation is supported by a favorable NPV framework while estimates improve to a 2026 EPS loss of $(0.80) from $(0.92), suggesting tighter expected cash burn. Its lead asset, Stenoparib, is advancing in a Phase 2 ovarian cancer trial and a newly announced Phase 2 recurrent SCLC trial that dosed its first patient in February 2026, while the DRP companion diagnostic may improve patient selection and clinical success rates. The investment case is further strengthened by durable efficacy signals, including median overall survival exceeding 25 months and two patients remaining on therapy beyond 29 months as of March 2026, alongside a large PARP market growing from ~$9.0 billion in 2023 toward over $21.0 billion by 2031.

Bears say

Allarity Therapeutics is a clinical-stage company with essentially no revenue, reporting about $0 million in fiscal Q2 2026 and a net loss of $3.4 million, or $(0.21) per share, underscoring its dependence on external financing rather than commercial cash flow. Its lead asset, stenoparib, remains far from de-risked, with long development challenges in advanced recurrent ovarian cancer and uncertainty around safety, efficacy, regulatory approval, and eventual commercialization. The negative outlook is further reinforced by balance sheet and liquidity risks, limited reimbursement prospects, and broad biotech sentiment and macro factors that could impair funding and valuation.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Oct 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.